But it's still unclear which new approaches in human therapeutics will pay off big; cancer and neuroscience are among the contenders
Despite the enormous amount of money invested in research and development of biotechnology-derived human therapeutics in the past two decades or so, biotech industry participants and observers say the future is still unclear.

Only 21 biotech drugs have been released so far, and many of those are bioengineered versions of substances that have been known and used for a long time, such as insulin and human growth hormone. During this time the industry has experienced spectacular rises and falls, both scientifically and financially, often fueled by hype and unrealistic expectations.

Currently in the pipeline, however, is the next generation of biotech drugs. And these drugs will take advantage of the latest discoveries of how cells work, targeting previously uncharacterized receptors on the surface of cells or moving directly into...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?